Reston, Va. —To facilitate the effective use of molecular imaging biomarkers in clinical trials, SNM’s Clinical Trials Network (CTN) this week co-sponsored the 2012 Molecular Medicine Tri-conference. With a core audience of scientists and executives from biotechnical and pharmaceutical industries, academia and government, the conference helped CTN to raise awareness of how the use of imaging can advance drug development with institutions and companies conducting clinical trials for various pharmaceuticals.
The SNM CTN provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of imaging biomarkers for clinical use. “With several lectures on translational imaging and PET biomarkers, the conference allowed CTN to explain to a large number of interested groups how incorporating molecular imaging in their research can improve the effectiveness of their trials,” said Jeffrey Yap, PhD, CTN Trial Design Committee chair. “The interface between pharmaceuticals and imaging continues to expand, including opportunities to guide pipeline development, pair diagnostics and therapeutics, use imaging to guide therapy and use imaging as an outcome measure.”
As part of its sponsorship of the meeting, CTN was part of a sponsored plenary, “Emerging Technologies and Industry Perspectives.” During this plenary session, Yap spoke on the latest accomplishments and projects of the CTN and how CTN works with companies to facilitate the use of molecular imaging in their trials. CTN also hosted a booth at the conference.
The Molecular Medicine Tri-conference, held February 19-23, 2012, in San Francisco, Calif., offered interactive lectures and discussions on diagnostics, drug development and discovery, informatics and cancer. Over 50 exhibitors and nearly 2,900 attendees were part of the 2011 conference.
For more information about the SNM Clinical Trials Network, visit www.snm.org/ctn.
SNM is an international scientific and medical organization dedicated to raising public awareness about what molecular imaging is and how it can help provide patients with the best health care possible. SNM members specialize in molecular imaging, a vital element of today’s medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated.
SNM’s more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snm.org.